



Clinical Updates in Breast Cancer From San Antonio
Clinical Update 4 – Abemaciclib or Ribociclib for High-Risk, HR+/HER2– Early Breast Cancer: Results
From the Phase 3 monarchE and NATALEE Trials

References

Tweet 2 References:

Harbeck N, Rastogi P, O'Shaughnessy J, et al. LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. *Ann Oncol.* 2023;34:S1256. doi:10.1016/j.annonc.2023.10.007

Hortobagyi G, Stroyakovsky D, Yardley D, et al. (GS03-03) Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2– early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. Presented at: SABCS; December 5–9 2023; San Antonio, TX. Accessed December 7, 2023.
<https://sabcs2023.eventscribe.net/fsPopup.asp?PresentationID=1335761&query=natalee&Mode=presentation>

Rugo HS, O'Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. *Ann Oncol.* 2022;33(6):616-627. doi:10.1016/j.annonc.2022.03.006

Slamon DJ, Stroyakovskiy D, Yardley DA, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2– early breast cancer: Primary results from the phase III NATALEE trial. *J Clin Oncol.* 2023;41(17_suppl):LBA500. doi:10.1200/JCO.2023.41.17_suppl.LBA500

Turner N, Reis-Filho J, Goetz M, et al. (GS03-06) Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial. Presented at: SABCS; December 5–9 2023; San Antonio, TX. Accessed December 6, 2023.
<https://sabcs2023.eventscribe.net/fsPopup.asp?PresentationID=1328565&query=monarche&Mode=presentation>

Additional References:

Fasching PA, Slamon D, Nowecki Z, et al. VP3-2023: Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HR+/HER2– early breast cancer (EBC). *Ann Oncol.* 2023;34(10):951-953. doi:10.1016/j.annonc.2023.08.007

KISQALI® (ribociclib). Prescribing information. Novartis Pharmaceuticals Corporation. Approved 2017. Revised October 2022.
<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092>

VERZENIO® (abemaciclib). Prescribing information. Eli Lilly and Company. Approved 2017. Revised March 2023.
<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716>



Glossary

Abema, abemaciclib
AE, adverse event
AI, aromatase inhibitor
ALN, axillary lymph node
CDK4/6i, cyclin-dependent kinase 4/6 inhibitor
DDFS, distant disease-free survival
DRFS, distant recurrence-free survival
EBC, early breast cancer
ET, endocrine therapy
G, grade
HER2-, human epidermal growth factor receptor 2 negative
HR, hazard ratio
HR+, hormone receptor positive
i, inhibitor
IDFS, invasive disease-free survival
N, lymph node
NS, not significant
NSAI, nonsteroidal aromatase inhibitor
OS, overall survival
w/, with